Bosutinib/bosutinib brand name and generic drug prices

Bosutinib/Bosutinib (Bosutinib), as a targeted oral drug for the treatment of chronic myelogenous leukemia (CML), has received widespread attention globally in recent years, especially providing a new option for patients who have failed or are resistant to TKI treatment. Although the drug has been approved and put into use in many countries such as the United States, Japan and Europe, as of now, bosutinib has not been officially included in the medical insurance system in mainland China, resulting in a large difference between its market price and the international version, and also posing challenges to patients' financial burden.

According to the latest overseas drug channel information, the more common versions of bosutinib’s original drug currently on the market include the Swiss version, the European version and the Turkish version. Among them, the Swiss and European versions of 500mg tablets are usually packed in 28 tablets/box and cost around 40,000 yuan, making them high-priced drugs. In comparison, the Turkish version has a more relaxed local drug pricing policy. The price of 28 tablets of 500mg is around 2,000 yuan, which is relatively cost-effective. Therefore, it has gradually become the focus of overseas drug purchasers. However, it should be noted that drug prices fluctuate slightly with exchange rate changes, and you still need to consult formal channels before purchasing.

On the other hand, the introduction of generic drugs has significantly reduced the cost of medication for patients. As a major country of generic drugs, India has many pharmaceutical companies such as Natco and Hetero launching generic versions of bosutinib. The common specifications are 100mg/120 tablets, and each box is priced at more than 1,000 yuan. Although these generic drugs have not yet been officially approved for marketing in mainland China, purchasing them through overseas channels has become an option for some patients. In terms of drug quality control such as active ingredients and dissolution, the Indian version of generic drugs usually follows generic drug approval standards and has a relatively stable basis for efficacy.

Reference materials:https://go.drugbank.com/drugs/DB06616